View Older Stories View More Recent Stories
-
Neuralstem (CUR) to Offer Common Stock
-
Neuralstem Announces Proposed Public Offering of Securities
-
Biocept (BIOC) Prices 5M Common Stock, Warrants Offering at $1/Share
-
Biocept, Inc. Announces Pricing Of $5 Million Public Offering Of Common Stock And Warrants
-
ROTH Capital Partners' Joseph Pantginis Interviewed by The Life Sciences Report
-
Global Water Resources, Inc. announces pricing of initial public offering
-
Roth Affirms Ballard Power (BLDP) at 'Buy' Following Q1 Results; Cost Controls Firm, Order Book Growing
-
Ring Energy, Inc. Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
-
Roth Affirms Ligand Pharma (LGND) at 'Buy' Following FDA Acceptance of Lundbeck's CE-Carbamazepine NDA Resubmission
-
Mark E. Rose Joins LiquidSpace Board of Directors
-
Roth Keeps AmpliPhi (APHB) at 'Buy' as AB-SA01 Shows Early Progress in Chronic Rhinosinusitis
-
Orphan Drug Exclusivity for Spectrum's (SPPI) Evomela is Important Increment for Ligand (LGND) - Roth Capital
-
Roth Capital Starts ID Systems (IDSY) at Buy
-
Synergy's (SGYP) Plecanatide Seen as 'Rare Gem' at Roth Capital
-
Roth Boosts PT on Argos Therapeutics (ARGS) to $18; Focus Remains on ADAPT, IDMC Looks
-
Rimini Street Announces Preliminary Fiscal 2016 Q1 Financial Results
-
Gemphire Therapeutics (GEMP) Files $60M IPO
-
The PIPEs Report Sees Small-Cap Equity Financing Growth at the End of Q1 2016
-
Roth Capital Affirms Celldex (CLDX) at 'Buy'; Says Growing Varli Profile Continues to be Impressive
-
Streetinsider.com's Hot Lunchtime Reads :(CPXX) (CLBS) (TAST) (RLYP)
-
Roth Capital Affirm Celator Pharma (CPXX) at 'Buy'; Says FLT3-ITD Patients Have a New Enemy in Vyxeos
-
Roth Capital Reinstates XO Group (XOXO) at Buy
-
Roth Capital Starts Mitek Systems (MITK) at Buy
-
Roth Capital Starts Shopify (SHOP) at Buy
-
Roth Sees AmpliPhi's (APHB) Termination of Intrexon (XON) ECC at 'Smart Move'; Affirms at 'Buy'
-
Roth Capital Starts Five9, Inc (FIVN) at Buy
-
Roth Capital Starts Glaukos Corporation (GKOS) at Buy
-
Synta Pharma (SNTA), Madrigal Pharma Enter All-Stock Merger Agreement
-
Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
-
Notable 52-Week Highs and Lows 4/13: (CPXX) (SID) High; (AGN) (IOTS) Low
-
Celator Pharmaceuticals (CPXX) Sees Second Day of Big Gains
-
UPDATE: Roth Sees Celator Pharma's (CPXX) Vyxeos Easily Supplementing Standard of Care 7+3 Therapy; Affirms at 'Buy'
-
Notable Analyst Rating Changes 4/11: (QSR) (BLMN) (GOOG) Upgraded; (GG) (CLMT) (POT) Downgraded
-
PlacementTracker Publishes Q1 2016 PIPE Market League Tables
-
Roth Capital Sees Significant Upside in FuelCell Energy (FCEL); Initiates Coverage at 'Buy'
-
Quantum Materials Closes Financing
-
Roth Remains Bullish on Ligand Pharma (LGND) as Revolade Gets Expanded Approval in Europe (NVS)
-
Lucas Energy (LEI) Announces $15M Equity Raise
-
Lucas Energy Secures $15 Million Financing To Fund Growth Initiative
-
Research Solutions Appoints Chad Cooper to Board of Directors
-
Pershing Gold Reports Analyst Coverage Initiated by ROTH Capital Partners
-
Roth Capital Starts Pershing Gold (PGLC) at Buy
-
Roth Trims PT on Sky Solar (SKYS) Following Q4 Results, Move to Unlock Shareholder Value
-
Roth Expects Full Approval of Regeneron (REGN) Dupilumab, Trims PT to $520
-
2 Million Transactions and Counting, LiquidSpace Seeks 100 Million Square Feet of Additional Office Space
-
Quest Resource Holding Corporation Closes $3.34 Million Underwritten Public Offering of Common Stock and Warrants
-
Historic 10-Year Anniversary of a Celebration of Heroes, Heart and Hope Gala in New York City Commemorating ‘A Decade of Difference’
-
Celator® Pharmaceuticals Closes $43.7 Million Underwritten Financing
-
BioLineRx's (BLRX) BL-8040's Phase 2 Data is Encouraging; Roth Affirms at 'Buy'
-
Seaport Global Expanding Equity Business

